Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q – IMPROVE CODEL: the NOA-18 trial

Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q – IMPROVE CODEL: the NOA-18 trial

Abstract Background Given the young age of patients with CNS WHO grade 2 and 3 oligodendrogliomas and the relevant risk of neurocognitive, functional, and quality-of-life impairment with the current aggressive standard of care treatment, chemoradiation with PCV, of the tumour located in the brain op...

Full description

Bibliographic Details
Main Authors: A. Wick, A. Sander, M. Koch, M. Bendszus, S. Combs, T. Haut, A. Dormann, S. Walter, M. Pertz, J. Merkle-Lock, N. Selkrig, R. Limprecht, L. Baumann, M. Kieser, F. Sahm, U. Schlegel, F. Winkler, M. Platten, W. Wick, T. Kessler
Format: Article
Language:English
Published: BMC 2022-06-01
Series:BMC Cancer
Subjects:
Qualified overall survival (qOS)
Neurocognition
Procarbazine, CCNU, vincristine (PCV)
CCNU and Temozolomide for Glioma (CETEG)
Health-related quality of life (HRQoL)
Oligodendroglioma
Online Access:https://doi.org/10.1186/s12885-022-09720-z

Internet

https://doi.org/10.1186/s12885-022-09720-z

Similar Items